The vaccine, called camupepimut, works by “teaching” the immune system to recognize and respond to seven different mutations in the KRAS gene, which are found in about 90 percent of pancreatic ductal adenocarcinomas and drive the cancer’s growth.
Pancreatic cancer is notoriously belligerent and can be tricky to treat, but a new clinical trial has suggested an experimental vaccine could offer hope to some patients.